The role of biopharma start-ups in bringing innovative therapies to the market has grown enormously. These waves of new specialist companies often have the most innovative approaches to targeting a disease, and big pharma has become increasingly reliant on their fresh ideas to power pipelines. 

The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.

After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.

Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.